The high cost of spasticity in multiple sclerosis to individuals and society

被引:18
作者
Stevenson, V. L. [1 ]
Gras, A. [2 ]
Bardos, J. I. [3 ]
Broughton, J. [4 ]
机构
[1] UCLH NHS Trust, Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England
[2] GfK, Market Access Hlth, Nurnberg, Germany
[3] Costello Med Consulting, Cambridge, England
[4] Bayer PLC, Hlth Econ Outcomes Res, Newbury, Berks, England
关键词
Multiple sclerosis; spasticity; pharmacoeconomic; disease burden; questionnaire; treatment costs; health-related quality of life; MANAGEMENT; PREVALENCE; HOME;
D O I
10.1177/1352458514566416
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Spasticity is an extremely common, distressing and disabling symptom of multiple sclerosis. Limited data suggest the associated health care costs correlate with increasing severity and place a high economic burden on individuals, health care systems and society. Objective: The aim of this study was to quantify the impact of multiple sclerosis spasticity on health care resources and the associated costs at different levels of severity in people with multiple sclerosis in the United Kingdom. Methods: An online survey was carried out to understand the resources used in the management of spasticity in multiple sclerosis. The questionnaire asked health care specialists to estimate their involvement and the resource use associated with different levels of spasticity, and the survey outputs were used to derive the resource costs. Results: The level and cost of care substantially increased with the degree of spasticity. Key factors contributing to high annual costs per patient were home care, hospital admissions and high-cost items, such as hospital beds. Conclusions: Based on the survey results, it can be assumed that managing spasticity early and effectively could result in substantial cost savings, in addition to the improvements in health-related quality of life.
引用
收藏
页码:1583 / 1592
页数:10
相关论文
共 28 条
  • [1] Berger T, 2013, EXPERT REV NEUROTHER, V13, P3, DOI [10.1586/ERN.13.3, 10.1586/ern.13.3]
  • [2] The value of early intervention in RA-a window of opportunity
    Breedveld, Ferdinand
    [J]. CLINICAL RHEUMATOLOGY, 2011, 30 : S33 - S39
  • [3] Cardarelli William J, 2012, Am J Manag Care, V18, pS315
  • [4] The management of multiple sclerosis patients
    Clanet, MG
    Brassat, D
    [J]. CURRENT OPINION IN NEUROLOGY, 2000, 13 (03) : 263 - 270
  • [5] Multiple sclerosis
    Compston, A
    Coles, A
    [J]. LANCET, 2002, 359 (9313) : 1221 - 1231
  • [6] Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
    Emery, P.
    Durez, P.
    Dougados, M.
    Legerton, C. W.
    Becker, J-C
    Vratsanos, G.
    Genant, H. K.
    Peterfy, C.
    Mitra, P.
    Overfield, S.
    Qi, K.
    Westhovens, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (03) : 510 - 516
  • [7] Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life
    Flachenecker, P.
    Henze, T.
    Zettl, U. K.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2014, 129 (03): : 154 - 162
  • [8] Goekoop-Ruiterman YPM, 2005, ARTHRITIS RHEUM-US, V52, P3381, DOI 10.1002/art.23364
  • [9] Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines
    Gold, Ralf
    Oreja-Guevara, Celia
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (12) : 55 - 59
  • [10] Spasticity Management in Multiple Sclerosis
    Hughes, Christina
    Howard, Ileana M.
    [J]. PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA, 2013, 24 (04) : 593 - +